2018 Primary Progressive Multiple Sclerosis (PPMS) Pipeline Insights – ResearchAndMarkets.com

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Primary Progressive Multiple Sclerosis (PPMS) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Primary Progressive Multiple Sclerosis (PPMS) pipeline products by developmental stage, product type, molecule type, and administration route.

The report provides a snapshot of the pipeline development for the Primary Progressive Multiple Sclerosis (PPMS)The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Primary Progressive Multiple Sclerosis (PPMS)The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Primary Progressive Multiple Sclerosis (PPMS)The report also covers the dormant and discontinued pipeline projects related to the Primary Progressive Multiple Sclerosis (PPMS)

F. Hoffmann-La Roche Ltd.Genzyme CorporationGlialogixKyorin Pharmaceutical Co.MedDay SASanthera Pharmaceuticals Holding AGTeva Pharmaceutical Industries Ltd.

2. Primary Progressive Multiple Sclerosis (PPMS) Overview

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs


SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/19/2018 01:27 PM/DISC: 07/19/2018 01:27 PM

Copyright Business Wire 2018.

Source link

Leave a Reply

Your email address will not be published.